Seegene, Inc. logo

Seegene, Inc. (096530)

Market Open
11 Aug, 06:30
KRX SM KRX SM
33,200. 00
+2,450
+7.9675%
1.44T Market Cap
- P/E Ratio
800% Div Yield
181,690 Volume
- Eps
30,750
Previous Close
Add Transaction
Day Range
30,150 33,200
Year Range
21,700 33,200
Want to track 096530 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

096530 trading today higher at ₩33,200, an increase of 7.9675% from yesterday's close, completing a monthly increase of 10.8514% or ₩3,250. Over the past 12 months, 096530 stock gained 38.3333%.
096530 pays dividends to its shareholders, with the most recent payment made on Apr 27, 2026. The next announced payment will be in In 3 days on Aug 14, 2026 for a total of ₩200.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Seegene, Inc. has completed 4 stock splits, with the recent split occurring on Apr 23, 2021.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).

096530 Chart

People also search for

Samsung Biologics Co., Ltd.
1,588,000
+1.211%
Celltrion Inc.
204,500
+1.7413%
ALTEOGEN Inc.
340,500
-2.1552%
Sk Biopharmaceuticals Co., Ltd.
90,600
+2.1421%
ABL Bio Inc.
92,300
-1.3889%

Seegene, Inc. (096530) FAQ

What is the stock price today?

The current price is ₩33,200.00.

On which exchange is it traded?

Seegene, Inc. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 096530.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 800%.

What is its market cap?

As of today, the market cap is 1.44T.

Has Seegene, Inc. ever had a stock split?

Seegene, Inc. had 4 splits and the recent split was on Apr 23, 2021.

Seegene, Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Jong-Yoon Chun CEO
KRX SM Exchange
KR7096530001 ISIN
South Korea Country
63 Employees
29 Jun 2026 Last Dividend
23 Apr 2021 Last Split
- IPO Date

Overview

Seegene, Inc. is a globally renowned company in the molecular diagnostics market, specializing in the development and manufacture of a wide array of diagnostics products. The company focuses on delivering innovative solutions for the detection of infectious diseases, including respiratory, gastrointestinal, and sexually transmitted infections, human papillomavirus, tuberculosis, and sepsis, among others. It also ventures into the detection of genetic mutations such as SNPs in significant genes. Established in the year 2000, Seegene has positioned itself as a leader in molecular diagnostics, leveraging cutting-edge technologies to provide reliable and efficient diagnostic tests. Headquartered in Seoul, South Korea, Seegene operates worldwide, significantly contributing to global health by facilitating early and accurate disease diagnosis. The company's strategic collaborations, such as with Werfen for the joint development of syndromic qPCR assays, highlight its commitment to advancing diagnostic solutions through partnerships and innovation.

Products and Services

  • Respiratory Disease Detection Products: These diagnostics tools are designed for the identification of pathogens causing respiratory infections. Utilizing sophisticated molecular technologies, Seegene's respiratory tests offer rapid and accurate detection, aiding in timely patient management and control of infectious disease spread.
  • Gastrointestinal Disease Detection Products: Aimed at diagnosing infections of the gastrointestinal tract, these products employ advanced molecular diagnostics to pinpoint the causative pathogens, crucial for appropriate treatment and patient care.
  • Human Papillomavirus Detection Products: Seegene's tests for HPV play a critical role in the screening and management of HPV-related diseases, offering high specificity and sensitivity in the detection of the virus.
  • Sexually Transmitted Infections Causative Pathogens Detection Products: These diagnostics solutions are tailored for the rapid and accurate identification of various sexually transmitted infections (STIs), facilitating effective treatment and prevention measures.
  • Tuberculosis Detection Products: Focused on the detection of Mycobacterium tuberculosis and its drug resistance, these products contribute significantly to the global fight against TB, offering tools for early diagnosis and monitoring of the disease.
  • Drug Resistance Products: Seegene offers tests for the detection of antimicrobial resistance, critical for guiding treatment decisions and combating the rise of drug-resistant infections.
  • Magicplex Sepsis Real-Time Test: This product is designed for the detection and identification of sepsis-causing pathogens, offering rapid results that can drastically improve patient outcomes through timely intervention.
  • Meningitis Detection Products: Aimed at identifying causative agents of meningitis, these diagnostics solutions provide crucial information for the effective management of this potentially life-threatening condition.
  • Detection of SNPs in Factor II, Factor V, and MTHFR Genes: Beyond infectious diseases, Seegene also provides products for the genetic testing of specific single nucleotide polymorphisms (SNPs), aiding in the assessment of genetic risk factors for certain conditions.

Contact Information

Address: Taewon Building
Phone: 82 2 2240 4000